Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

Presentations will cover real-world data on DAYBUE® (trofinetide) and exploratory analyses of NUPLAZID® (pimavanserin) in Parkinson's disease psychosis

Apr. 20, 2026 at 3:18am

Got story updates? Submit your updates here. ›

A minimalist, glowing neon outline of a stylized brain structure against a dark background, conveying the neurological focus of Acadia Pharmaceuticals' research.Acadia Pharmaceuticals' research into neurological conditions aims to shed light on the inner workings of the brain through innovative therapies.Chicago Today

Acadia Pharmaceuticals Inc. announced that it will present multiple data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting. The presentations will include real-world data on DAYBUE® (trofinetide) for Rett syndrome and exploratory analyses of NUPLAZID® (pimavanserin) in Parkinson's disease psychosis. The company will also debut translational and pharmacokinetic research supporting the continued development of ACP-711 for essential tremor.

Why it matters

These data presentations reflect Acadia's ongoing commitment to advancing scientific knowledge and understanding of neurological conditions, including Rett syndrome, Parkinson's disease psychosis, and essential tremor. The findings could help inform future treatment approaches and clinical management for patients living with these complex neurological disorders.

The details

Acadia will present real-world data from the LOTUS study evaluating the benefits and tolerability of DAYBUE® (trofinetide) in adults with Rett syndrome. The company will also present exploratory analyses on the heterogeneity in treatment response trajectories and the impact of baseline sleep disturbances among Parkinson's disease psychosis patients treated with NUPLAZID® (pimavanserin). Additionally, Acadia will debut translational and pharmacokinetic research supporting the continued development of ACP-711, an investigational drug for essential tremor.

  • The AAN Annual Meeting will take place April 18–22, 2026 in Chicago, IL.
  • The DAYBUE® and NUPLAZID® data presentations will be on Wednesday, April 22, 2026.
  • The ACP-711 data presentations will be on Tuesday, April 21, 2026.

The players

Acadia Pharmaceuticals Inc.

An American pharmaceutical company focused on developing and commercializing innovative treatments for neurological and rare diseases.

DAYBUE® (trofinetide)

A synthetic analog of the N-terminal tripeptide of insulin-like growth factor-1 indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.

NUPLAZID® (pimavanserin)

A selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors, indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

ACP-711

An investigational drug being developed by Acadia Pharmaceuticals for the treatment of essential tremor.

Got photos? Submit your photos here. ›

What’s next

The presentations at the 2026 AAN Annual Meeting will provide important insights into Acadia's portfolio of neurological treatments, which could inform future clinical development and potential regulatory submissions.

The takeaway

Acadia Pharmaceuticals is continuing to make progress in its efforts to address unmet needs for patients living with complex neurological disorders, such as Rett syndrome, Parkinson's disease psychosis, and essential tremor, through its robust pipeline of innovative therapies.